Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Transcription factors in tumor diagnosis].

Der Pathologe·2018
Same author

[Not Available].

Klinische Neuroradiologie·2016
Same author

The Ebola epidemic and public health response.

British medical bulletin·2016
Same author

Well-differentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections.

Digestion·2014
Same author

Successful selective internal radiotherapy (SIRT) in a patient with a malignant solid pseudopapillary pancreatic neoplasm (SPN).

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2012
Same author

[In situ hybridization in clinical pathology. Significance of polysomy 17 for HER2 determination and genetic tumor heterogeneity in breast cancer].

Der Pathologe·2012

Related Experiment Video

Updated: Jul 9, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

[CUP syndrome: are there advances?].

R Moll1

  • 1Institut für Pathologie, Philipps-Universität Marburg.

Verhandlungen Der Deutschen Gesellschaft Fur Pathologie
|November 27, 2007
PubMed
Summary

Cancer of unknown primary (CUP) syndrome requires precise diagnosis using immunohistochemistry. Identifying specific tumor markers aids in classifying CUP and guiding targeted therapies for better patient outcomes.

Area of Science:

  • Oncology
  • Pathology

Context:

  • Metastatic cancer of unknown primary (CUP) site constitutes 2-5% of malignant tumors.
  • Distinguishing initial CUP from true CUP syndrome is crucial for diagnosis and treatment.
  • Immunohistochemistry is a key diagnostic tool for initial CUP, utilizing a two-step algorithmic approach with marker panels.

Purpose:

  • To highlight the importance of immunohistochemistry in diagnosing and classifying cancer of unknown primary (CUP) syndrome.
  • To discuss the characteristics of true CUP tumors, including their metastatic patterns and poor prognosis.
  • To emphasize the need for further research, including gene expression profiling, for improved diagnosis and therapy.

Summary:

  • Immunohistochemistry, employing marker panels and organ-specific markers, aids in classifying initial CUP.

Related Experiment Videos

Last Updated: Jul 9, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

  • True CUP tumors exhibit early metastatic phenotypes and unusual patterns, often with poor prognosis, and may show unique immunohistochemical profiles.
  • Histologic and immunohistochemical examination are vital for identifying therapy-responsive CUP subgroups.

    • Impact:

    • Accurate diagnosis and classification of CUP syndrome can lead to more specific therapeutic regimens.
    • Improved understanding of CUP pathogenesis through future research may enhance diagnostic and therapeutic strategies.
    • Pathology's role is essential in elucidating CUP pathogenesis, improving diagnosis, and developing targeted treatments.